Design and optimisation of new chemical entities that prevent the neurotoxic oligomerization and misfolding of both ß-amyloid and tau proteins: A disease modifying therapeutics approach for Alzheimer’s Dementia

Award Number
Status / Stage
19 July 2013 -
18 July 2016
Duration (calculated)
02 years 11 months
Wellcome Trust
Funding Amount
Contracted Centre
Treventis Corporation
Contracted Centre Webpage
Principal Investigator
Prof Donald Weaver
PI Contact
WHO Catergories
Development of novel therapies
Disease Type
Alzheimer's Disease (AD)

CPEC Review Info
Reference ID314
ResearcherReside Team


Award Number100481/Z/12/Z
Status / StageCompleted
Start Date20130719
End Date20160718
Duration (calculated) 02 years 11 months
Contracted CentreTreventis Corporation
Contracted Centre Webpage
Funding Amount£920,811.00


Wellcome Trust has awarded a grant to TREVENTIS Corporation to discover a disease-modifying drug for the treatment of Alzheimer’s disease (AD). Numerous studies support the causative role of ß-amyloid (Aß) and tau in the aetiopathogenesis of AD.These proteins tend to abnormally “clump” (protein misfolding) and give rise to neurotoxic aggregates of ß-amyloid (plaques) and tau (“tangles”), the pathological hallmarks of AD. In vitro studies have identified that Aß can be neurotoxic when in small aggregates. Since disease-modifying drugs represent the most desirable therapeutic approach to AD, protein misfolding of Aß and tau represents a potential target in the rational design of a drug. The ultimate goal of this research is to discover a disease-modifying new chemical entity for the treatment of AD that is efficacious and safe. This goal will be achieved by optimizing a class of small organic molecules capable of binding to both ß-amyloid and tau, blocking their misfolding. A new series has recently been identified that are drug-like, potent anti-aggregants and penetrate the Central Nervous System. Funding under this award will enable the discovery of a lead candidate with completed pre-clinical pharmacokinetic and toxicology package.